 |
|
|
| |
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis (PBC): Interim Results for 2 Years From the ASSURE Study
|
| |
| |
EASL 2024 June 5-8
Palak J. Trivedi1*, Cynthia Levy2, Kris V. Kowdley3, Stuart C. Gordon4, Christopher L. Bowlus5, Maria Carlota Londoņo Hurtado6, Gideon M. Hirschfield7, Aliya Gulamhusein8, Eric J. Lawitz,9 Alejandra Villamil10, Alma Ladron de Guevara Cetina11, Marlyn Mayo12,
Ziad Younes13, Oren Shibolet14, Kidist Yimam15, Daniel Pratt16, Jeong Heo17, Ulrike Morgera18, Pietro Andreone19, Andreas E. Kremer20, Christophe Corpechot21, Aparna Goel22, Adam Peyton23, Hany Elbeshbeshy24, Carrie Heusner25,
Sarah Proehl25, Shuqiong Zhuo25, Daria B. Crittenden25, and Charles A. McWherter25
|
| |
|
|
|
|
|
